Literature DB >> 8071311

Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver.

S Ruff-Jamison1, Z Zhong, Z Wen, K Chen, J E Darnell, S Cohen.   

Abstract

Previous studies demonstrated that the intraperitoneal injection of epidermal growth factor (EGF) into mice resulted in the appearance, within minutes, of several tyrosine-phosphorylated proteins in liver nuclei. Two of these proteins have been identified as the transcription factors p91/p84 (Stat1 alpha/1 beta) (Ruff-Jamison, S., Chen, K., and Cohen, S. (1993) Science 261, 1733-1736). We have now identified, by Western blotting and immunoprecipitation, an additional EGF-modulated transcription factor, Stat3. We find that Stat3 is tyrosine-phosphorylated and present in mouse liver nuclei following either EGF or lipopolysaccharide administration. Gel shift analyses show that Stat3 is capable of specifically binding the SIE (a DNA sequence present in the c-fos promoter). Three active SIE binding complexes (SIF A, B, and C) exist in the nucleus after the administration of EGF: one complex that contains Stat3, one that contains Stat1, and a third complex that appears to contain both proteins. Only one active SIE binding complex, containing Stat3, was detected after the administration of lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071311

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Activation and association of Stat3 with Src in v-Src-transformed cell lines.

Authors:  X Cao; A Tay; G R Guy; Y H Tan
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Origins of growth factors: NGF and EGF.

Authors:  Stanley Cohen
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

4.  TFII-I enhances activation of the c-fos promoter through interactions with upstream elements.

Authors:  D W Kim; V Cheriyath; A L Roy; B H Cochran
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

5.  Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein.

Authors:  L E Johannessen; S L Knardal; I H Madshus
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

6.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor.

Authors:  Y Yamada; I Kirillova; J J Peschon; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

7.  A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation.

Authors:  D Besser; J F Bromberg; J E Darnell; H Hanafusa
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

8.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins.

Authors:  M L Vignais; H B Sadowski; D Watling; N C Rogers; M Gilman
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

9.  Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.

Authors:  K Kunisada; S Negoro; E Tone; M Funamoto; T Osugi; S Yamada; M Okabe; T Kishimoto; K Yamauchi-Takihara
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

10.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.